Rescue of beta-cell exhaustion by diazoxide after the development of diabetes mellitus in rats with streptozotocin-induced diabetes

European Journal of Pharmacology

Volumn 453, Issue 1, 2002, Pages 141-148

  Matsuda, Masafumi ^a   Kawasaki, Fumiko ^a   Mikami, Yoshiki ^a   Takeuchi, Yasuo ^a   Saito, Mieko ^a   Eto, Masaaki ^a   Kaku, Kohei ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Beta cell damage; Diabetes, rat; Diazoxide; Streptozotocin induced diabetes

Indexed keywords

DIAZOXIDE; GLUCOSE; INSULIN; MESSENGER RNA; POTASSIUM CHANNEL STIMULATING AGENT; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL PROTECTION; CELL SIZE; CONTROLLED STUDY; DISEASE COURSE; GLUCOSE TOLERANCE TEST; HISTOLOGY; IMMUNOHISTOCHEMISTRY; INSULIN RELEASE; MALE; NONHUMAN; PANCREAS; PANCREAS DISEASE; PANCREAS ISLET; PANCREAS ISLET BETA CELL DYSFUNCTION; PRIORITY JOURNAL; RAT; RAT STRAIN; STREPTOZOCIN DIABETES; TISSUE LEVEL;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIAZOXIDE; ISLETS OF LANGERHANS; MALE; RATS; RATS, WISTAR; STREPTOZOCIN;

EID: 0037131008     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02389-0     Document Type: Article

References (35)

1. Aizawa T., Taguchi N., Sato Y., Nakabayashi T., Kobuchi H., Hidaka H., Nagasawa T., Ishihara F., Itoh N., Hashizume K. Prophylaxis of genetically determined diabetes by diazoxide: a study in a rat model of naturally occurring obese diabetes. J. Pharmacol. Exp. Ther. 275:1995;194-199.
2. Alemzadeh R., Holshouser S. Effect of diazoxide on brain capillary insulin receptor binding and food intake in hyperphagic obese Zucker rats. Endocrinology. 140:1999;3198-3202.
3. Alemzadeh R., Jacobs W., Pitukcheewanont P. Antiobesity effect of diazoxide in obese Zucker rats. Metabolism. 45:1996;334-341.
4. Alemzadeh R., Langley G., Upchurch L., Smith P., Slonim A.E. Beneficial effect of diazoxide in obese hyperinsulinemic adults. J. Clin. Endocrinol. Metab. 83:1998;1911-1915.
5. Anonymous Diazoxide: a review of its pharmacological properties and therapeutic use in hypertensive crises. Drugs. 2:1971;78-137.
6. Basabe J.C., Pivetta O.H., de Bruno L.F., Cresto J.C., Aparicio N.J. A temporal study of somatostatin secretion and its inhibitory effect in genetically diabetic mice (C57BL/KsJ-db/db). Endocrinology. 113:1983;1927-1934.
7. Bjork E., Berne C., Kampe O., Wibell L., Oskarsson P., Karlsson F.A. Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes. Diabetes. 45:1996;1427-1430.
8. Bjork E., Berne C., Karlsson F.A. Induction of beta-cell rest in type 1 diabetes. Studies on the effects of octreotide and diazoxide. Diabetes Care. 21:1998;427-430.
9. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
10. Culbert S., Sharp R., Rogers M., Felts P., Burr I.M. Diazoxide modification of streptozotocin-induced diabetes in rats. Diabetes. 23:1974;282-286.
11. DeFronzo R.A. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes. 37:1988;667-687.
12. Gomis R., Plaza C., Malaisse W.J. Diazoxide-induced long-term hyperglycemia: I. Preservation of B-cell insulin-releasing capacity. Diabetes Res. 9:1988;183-186.
13. Greenwood R.H., Mahler R.F., Hales C.N. Improvement in insulin secretion in diabetes after diazoxide. Lancet. 1(7957):1976;444-447.
14. Grimmsmann T., Rustenbeck I. Direct effects of diazoxide on mitochondria in pancreatic B-cells and on isolated liver mitochondria. Br. J. Pharmacol. 123:1998;781-788.
15. Hiramatsu S., Hoog A., Moller C., Grill V. Treatment with diazoxide causes prolonged improvement of beta-cell function in rat islets transplanted to a diabetic environment. Metabolism. 49:2000;657-661.
16. Junod A., Lambert A.E., Stauffacher W., Renold A.E. Diabetogenic action of streptozotocin: relationship of dose to metabolic response. J. Clin. Invest. 48:1969;2129-2139.
17. Karlsson F.A., Bjork E. Beta-cell rest: a strategy for the prevention of autoimmune diabetes. Autoimmunity. 26:1997;117-122.
18. Kosaka K., Kuzuya T., Akanuma Y., Hagura R. Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment. Diabetologia. 18:1980;23-28.
19. Kullin M., Li Z., Hansen J.B., Bjork E., Sandler S., Karlsson F.A. K(ATP) channel openers protect rat islets against the toxic effect of streptozotocin. Diabetes. 49:2000;1131-1136.
20. Leahy J.L., Bumbalo L.M., Chen C. Diazoxide causes recovery of beta-cell glucose responsiveness in 90% pancreatectomized diabetic rats. Diabetes. 43:1994;173-179.
21. Lee S. Effects of diazoxide on insulin secretion and metabolic efficiency in the db/db mouse. Life Sci. 28:1981;1829-1840.
22. Malaisse W.J. The anomeric malaise: a manifestation of B-cell glucotoxicity. Horm. Metab. Res. 23:1991;307-311.
23. Miwa I., Okudo J., Maeda K., Okuda G. Mutarotase effect on colorimetric determination of blood glucose with D-glucose oxidase. Clin. Chim. Acta. 37:1972;538-540.
24. Rossetti L., Shulman G.I., Zawalich W., DeFronzo R.A. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J. Clin. Invest. 80:1987;1037-1044.
25. Rossetti L., Giaccari A., DeFronzo R.A. Glucose toxicity. Diabetes Care. 13:1990;610-630.
26. Saini K.S., Thompson C., Winterford C.M., Walker N.I., Cameron D.P. Streptozotocin at low doses induces apoptosis and at high doses causes necrosis in a murine pancreatic beta-cell line, INS-1. Biochem. Mol. Biol. Int. 39:1996;1229-1236.
27. Sato Y., Ishihara F., Hashizume K., Aizawa T. B-cell hyperresponsiveness to glucose in NIDDM during prediabetes. Adv. Exp. Med. Biol. 426:1997;385-387.
28. Shimaya A., Kurosaki E., Nakano R., Hirayama R., Shibasaki M., Shikama H. The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice. Metabolism. 49:2000;411-417.
29. Sjoholm A. Regulation of insulinoma cell proliferation and insulin accumulation by peptides and second messengers. Ups. J. Med. Sci. 100:1995;201-216.
30. Smulson M.E., Schein P., Mullins D.W. Jr., Sudhakar S. A putative role for nicotinamide adenine dinucleotide-promoted nuclear protein modification in the antitumor activity of N-methyl-N-nitrosourea. Cancer Res. 37:1977;3006-3012.
31. Sunaga Y., Inagaki N., Gonoi T., Yamada Y., Ishida H., Seino Y., Seino S. Troglitazone but not pioglitazone affects ATP-sensitive K(+) channel activity. Eur. J. Pharmacol. 381:1999;71-76.
32. Surwit R.S., Dixon T.M., Petro A.E., Daniel K.W., Collins S. Diazoxide restores beta3-adrenergic receptor function in diet-induced obesity and diabetes. Endocrinology. 141:2000;3630-3637.
33. Szewczyk A., Marban E. Mitochondria: a new target for K channel openers? Trends Pharmacol. Sci. 20:1999;157-161.
34. + channel in mouse pancreatic beta-cells. Pflugers Arch. 407:1986;493-499.
35. Xiong Y., Harmon C.S. Evidence that diazoxide promotes calcium influx in mouse keratinocyte cultures by membrane hyperpolarization. Skin Pharmacol. 8:1995;309-318.